GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc. (A subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd.), are Dominating the Global Menstrual Cramps Treatment Market in 2021

Global Menstrual Cramps Treatment Market is expected to grow with the CAGR of 7.8% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-menstrual-cramps-treatment-market

Global menstrual cramps treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global menstrual cramps treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • in October 2018, Nobelpharma Co., Ltd. announced the market launch of its drug named, Jemina Tablets (levonorgestrel – ethinylestradiol compound formulation) for the indication of dysmenorrhea or painful periods. The company also underwent strategic business partnership with ASKA Pharmaceutical Co., Ltd., a specialty pharmaceutical company working in the field of obstetrics and gynaecology to promote the sales and distribution of this drug. This product launch and partnership done by the company has increased its demand and sales in the future.

GlaxoSmithKline plc. is the dominating player in global menstrual cramps treatment market. The other key players existing in the market includes Bayer AG, Pfizer Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd.), Color Seven Co., Ltd., Beurer GmbH, Mylan N. V. (A part of Viatris Inc.), Boehringer Ingelheim International GmbH, PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation, LIVIA, Alvogen, Cumberland Pharmaceuticals Inc., Lupin Pharmaceuticals, Inc. (a subsidiary of LUPIN), Janssen Pharmaceuticals, Inc. (A subsidiary of Johnson & Johnson Services, Inc.), Sun Pharmaceutical Industries Ltd.

GlaxoSmithKline plc

GlaxoSmithKline plc was founded in 1715 and is headquartered in Middlesex U.K. They utilize the most recent innovation to bring genuine, human help to assist individuals with accomplishing their wellbeing objectives through supportable way of life change. Company mainly focus on the vaccines, consumer healthcare products, dermatology and others and dealing in the business segments such as pharmaceuticals, vaccines, consumer healthcare and among which pharmaceuticals is the market focussed segment. The product categories provided by the company are Our prescription medicines and vaccines, our consumer healthcare products, VIV healthcare, stiefel- dermatology among which our consumer healthcare products is the market focused category.

  • In March 2018, GlaxoSmithKline PLC., declared the successful agreement with Novartis to acquire full ownership of consumer healthcare business. This agreement helped company to escalate product portfolio and revenue growth of the company.

The company has presence across North America, Europe, Asia-Pacific, Middle East & Africa, South & Central America and earning revenue from its various subsidiaries such as 1506369 Alberta ULC (Canada), Action Potential Venture Capital Limited (England), Adechsa GmbH (Switzerland), Alenfarma – Especialidades Farmaceuticas, Limitada (Portugal), Allen & Hanburys Pharmaceutical Nigeria Limited (Nigeria) among others.

Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)

Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc) is headquartered in Titusville, New Jersey. The company is focusing on cardiovascular & metabolism, immunology, infectious diseases & vaccines, neuroscience, oncology and pulmonary hypertension therapeutic area. Moreover, the company is exclusively concentrating on bringing life-saving and life-changing solutions, the company provide products such as Micronor, Necon, Ortho, Ortho M-21, Ortho Novum, Ortho Tri-Cyclen, Ortho-Cyclen, Ortho-Novum, Nizoral Cream, Nizral, Nobligan, Nucynta, Motilium among many others among which Micronor, Necon, Ortho, Ortho M-21, Ortho Novum, Ortho Tri-Cyclen, Ortho-Cyclen, Ortho-Novum are the market focused segments.

For instance-

  • In August 2012, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson services, Inc.) has settled a lawsuit filed when Watson attempted to market a generic version of one of its contraceptive drugs.

The company has wide presence across Africa, Middle East, Americas, Asia-Pacific, and Europe.

Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.):

Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.). was founded in 1901 and is headquartered in New Jersey, U.S. The company is highly focusing on generic and specialty medicines portfolio as well as concentrating on strengthening consumer awareness of the benefits of generic medicines through partnerships and digital marketing programs. The company provides products such as generic medicines, biopharmaceuticals, specialty medicines among which generic medicines is the market focussed category.

For instance-

  • In July 2020, Teva Pharmaceuticals USA, Inc., which holds Takeda a joint business venture in the Japanese market, announced a new strategy for its local commercial operations. This strategy has enhanced the company's presence in the Japanese market and propels its revenue growth.

The company has wide presence across North America.